AquaBounty Technologies (NASDAQ:AQB – Get Free Report) and Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.
Earnings & Valuation
This table compares AquaBounty Technologies and Ligand Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AquaBounty Technologies | $2.47 million | 1.72 | -$18.49 million | ($0.69) | -1.19 |
| Ligand Pharmaceuticals | $268.09 million | 21.92 | $124.45 million | $2.24 | 131.17 |
Ligand Pharmaceuticals has higher revenue and earnings than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares AquaBounty Technologies and Ligand Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AquaBounty Technologies | N/A | -174.01% | -43.18% |
| Ligand Pharmaceuticals | 20.27% | 5.22% | 2.74% |
Risk and Volatility
AquaBounty Technologies has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.
Institutional and Insider Ownership
8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 1.0% of AquaBounty Technologies shares are held by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations and price targets for AquaBounty Technologies and Ligand Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AquaBounty Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Ligand Pharmaceuticals | 0 | 1 | 8 | 0 | 2.89 |
Ligand Pharmaceuticals has a consensus price target of $355.38, indicating a potential upside of 20.95%. Given Ligand Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than AquaBounty Technologies.
Summary
Ligand Pharmaceuticals beats AquaBounty Technologies on 12 of the 13 factors compared between the two stocks.
About AquaBounty Technologies
AquaBounty Technologies was a biotechnology company focused on developing land-based aquaculture and genetically engineered Atlantic salmon. Its best-known product, AquAdvantage Salmon, was designed to grow to market size faster than conventional farmed Atlantic salmon. The company raised salmon in recirculating aquaculture systems, which filter and reuse water. Its operations included facilities in the United States and Canada, and it developed its business around supplying salmon to the North American market.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Receive News & Ratings for AquaBounty Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AquaBounty Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
